IMMLT23021 // ACR-368-201 (GOG 3082) // Guercio
Basic Study Information
Purpose:
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368
as monotherapy or in combination with ultralow dose gemcitabine in participants with
platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma
based on Acrivon's OncoSignature® test status.
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Brendan Guercio
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search